[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352860-105":59,"doc-detail-352860-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rate-of-mgus-progression-to-haematological-malignancies-a-systematic-review","Rate of MGUS Progression to Haematological Malignancies: A Systematic Review","","Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre-cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Clinical guidelines estimate malignant progression from MGUS to haematological malignancy (HM) at ~1% per year, yet published rates vary widely. A systematic review searched four databases up to 28 March 2024, using meta-analysis and narrative synthesis, incorporating 46 studies from 17 countries to estimate progression to HM and MM.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rate-of-mgus-progression-to-haematological-malignancies-a-systematic-review/352860/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rate-of-mgus-progression-to-haematological-malignancies-a-systematic-review/352860.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MGUS and why does it matter clinically?","Question",{"text":112,"@type":113},"MGUS is a benign premalignancy that typically precedes multiple myeloma and other lymphoproliferative disease. Malignant progression is the central concern in MGUS management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the systematic review conducted?",{"text":117,"@type":113},"Four electronic databases (MEDLINE, EMBASE, PubMed, Web of Science) were searched from inception through 28 March 2024. Studies reporting progression outcomes were summarized using meta-analysis and narrative synthesis.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the review estimate for progression rates to HM and MM?",{"text":121,"@type":113},"Random-effects meta-analysis estimated 12 events per 1000 person-years to HM (1.2% per year) and 8 per 1000 person-years to MM (0.8% per year), with substantial heterogeneity across studies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352860,1790153466,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","European Journal of Haematology  \nORIGINAL ARTICLE  OPEN ACCESS   \nRate of MGUS Progression to Haematological Malignancies: A Systematic Review  \nStephen James Quinn1  | Chris Cardwell1 | Lesley Ann Anderson2,3 | Charlene McShane1  \n1Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland | 2Biostatistics & Health Data Science, Institute of Applied Health Sciences,  \nUniversity of Aberdeen, Aberdeen, Scotland | 3Interdisciplinary Institute, Vice Principals Office, University of Aberdeen, Aberdeen, Scotland Correspondence: Stephen James Quinn ([squinn449@qub.ac.uk](squinn449@qub.ac.uk)) | Charlene McShane ([c.mcshane@qub.ac.uk](c.mcshane@qub.ac.uk))  \nReceived: 19 September 2025 | Revised: 20 November 2025 | Accepted: 8 December 2025  \nKeywords: epidemiology | malignant progression | monoclonal gammopathy of undetermined significance | myeloma | systematic review  \nABSTRACT  \nMonoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre-cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM) . Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely. To address this discrepancy, a systematic review was conducted, investigating MGUS's rate of malignant progression to HM and MM alone. Four electronic databases were searched from inception to 28 March 2024 for articles reporting these outcomes; articles were summarised using meta-analysis and narrative synthesis. Findings were incorporated from n = 46 studies, published between 1991 and 2024 and conducted across n = 17 countries. Median follow-up ranged from 1.3 to 34.2 years and sample sizes ranged from n = 63 to 17,963 . In random-effects meta-analysis, n = 13 studies reported on MGUS progression to HM and n = 12 reported on progression to MM. The overall estimates of malignant progression events were 12 per 1000 person-years to HM, equivalent to 1.2% per year (95% CI: 1.0%–1.5%) and 8 per 1000 person-years to MM or 0.8% per year (95% CI: 0.7%–1.1%), with substantial heterogeneity between studies (I2 : 96.7% and 95.8%, respectively). Progression rates varied widely in narrative synthesis; at 10 years, studies reported annual MGUS progression rates of 6.6%–33.6% to HM and 7.0%–28.5% to MM. While progression rates aligned with clinical guidelines overall, studies' varied findings present opportunities for further research, exploring the impact of world region, follow-up duration, and study methods. Considering this, caution should be taken when informing clinicians and patients about the risk of progression from MGUS to MM.  \n1 | Introduction  \nMonoclonalgammopathy ofundetermined significance (MGUS) is a benign premalignancy [1], typically preceding multiple myeloma (MM) [2] . The clinical criteria for MGUS are \u003C 30 g/L monoclonal protein (M-protein) in serum, \u003C 10% bone marrow (BM) infiltration by clonal plasma cells, and no symptoms indicating MM or other lymphoproliferative disease [3] . Recent population-based screening from 2016 in Iceland has estimated that MGUS is prevalent in 4.9% of individuals aged 40+ years [4], and other studies indicate a higher MGUS prevalence in older [5], Black [5] and male populations [6, 7] .  \nMalignant progression to MM or other haematological malignancies (HMs) [8] is the main concern in MGUS management [3]. The International Myeloma Working Group (IMWG) advises regular follow-up in patients with MGUS to identify malignant progression early, aiming to improve symptom management and survival outcomes [3] .  \nCurrent guidelines recognise MGUS's rate of malignant progression as ‘around 1% per year’ [3], based on a large study conducted in Minnesota by Kyle et al. [9] While this indicates that around 5% of MGUS cases will progress to HM at 5 years, other studies have reported rates as low as 3.1%[10] and as high as  \nThis is an open access article under the te","cbCaieNc4q9sPIj0","https://ap.wps.com/l/cbCaieNc4q9sPIj0","pdf",988290,18,"English","# Introduction\n## MGUS criteria and prevalence\n## Malignant progression concern and management\n## Clinical guidelines and variability\n# Methods\n## Searches\n## Study management and screening","[{\"question\":\"What is MGUS and why does it matter clinically?\",\"answer\":\"MGUS is a benign premalignancy that typically precedes multiple myeloma and other lymphoproliferative disease. Malignant progression is the central concern in MGUS management.\"},{\"question\":\"How was the systematic review conducted?\",\"answer\":\"Four electronic databases (MEDLINE, EMBASE, PubMed, Web of Science) were searched from inception through 28 March 2024. Studies reporting progression outcomes were summarized using meta-analysis and narrative synthesis.\"},{\"question\":\"What did the review estimate for progression rates to HM and MM?\",\"answer\":\"Random-effects meta-analysis estimated 12 events per 1000 person-years to HM (1.2% per year) and 8 per 1000 person-years to MM (0.8% per year), with substantial heterogeneity across studies.\"}]","Rate of MGUS Progression to Haematological Malignancies: A Systematic Review | PDF",1790101782,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a20375f941263cca03c0b1f341ac4b4.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80ecd289fa64f91db83e98c12e060bc7.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae95e2da117c36445266673250a25f88.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bacf1eb95b75b2466a743da0b53c3dd5.webp",980,1287]